Upneeq is a drug owned by Rvl Pharmaceuticals Inc. It is protected by 12 US drug patents filed from 2020 to 2023 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 16, 2039. Details of Upneeq's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11324722 | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | Active |
| US11311515 | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | Active |
| US11541036 | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | Active |
| US11103482 | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | Active |
| US10940138 | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | Active |
| US10799481 | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | Active |
| US11701343 | Compositions and methods for treating ocular disorders |
Dec, 2039
(15 years from now) | Active |
| US10898573 | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | Active |
| US10814001 | Oxymetazoline compositions |
Dec, 2039
(15 years from now) | Active |
| US8357714 | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(6 years from now) | Active |
| US9867808 | Compositions and methods for non-surgical treatment of Ptosis |
Aug, 2031
(6 years from now) | Active |
| US10912765 | Compositions and methods for non-surgical treatment of ptosis |
Aug, 2031
(6 years from now) | Active |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Upneeq's patents.
Latest Legal Activities on Upneeq's Patents
Given below is the list of recent legal activities going on the following patents of Upneeq.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Yr, Small Entity | 17 Jul, 2024 | US8357714 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Apr, 2024 | US10799481 |
| Payment of Maintenance Fee, 4th Yr, Small Entity | 12 Apr, 2024 | US10814001 |
| Recordation of Patent Grant Mailed Critical | 18 Jul, 2023 | US11701343 |
| Patent Issue Date Used in PTA Calculation Critical | 18 Jul, 2023 | US11701343 |
| Electronic Review Critical | 18 Jul, 2023 | US11701343 |
| Patent eGrant Notification | 18 Jul, 2023 | US11701343 |
| Email Notification Critical | 18 Jul, 2023 | US11701343 |
| Mail Patent eGrant Notification | 18 Jul, 2023 | US11701343 |
| Recordation of Patent eGrant | 18 Jul, 2023 | US11701343 |
FDA has granted several exclusivities to Upneeq. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Upneeq, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Upneeq.
Exclusivity Information
Upneeq holds 1 exclusivities. All of its exclusivities have expired in 2023. Details of Upneeq's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Jul 08, 2023 |
US patents provide insights into the exclusivity only within the United States, but Upneeq is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Upneeq's family patents as well as insights into ongoing legal events on those patents.
Upneeq's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Upneeq's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 16, 2039 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Upneeq Generic API suppliers:
Oxymetazoline Hydrochloride is the generic name for the brand Upneeq. 1 company has already filed for the generic of Upneeq. Check out the entire list of companies who have already received approval for Upneeq's generic
Alternative Brands for Upneeq
Upneeq which is used for correcting drooping eyelids., has several other brand drugs using the same active ingredient (Oxymetazoline Hydrochloride). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
Apart from brand drugs containing the same ingredient, some generics have also been filed for Oxymetazoline Hydrochloride, Upneeq's active ingredient. Check the complete list of approved generic manufacturers for Upneeq
About Upneeq
Upneeq is a drug owned by Rvl Pharmaceuticals Inc. It is used for correcting drooping eyelids. Upneeq uses Oxymetazoline Hydrochloride as an active ingredient. Upneeq was launched by Rvl Pharms in 2020.
Approval Date:
Upneeq was approved by FDA for market use on 08 July, 2020.
Active Ingredient:
Upneeq uses Oxymetazoline Hydrochloride as the active ingredient. Check out other Drugs and Companies using Oxymetazoline Hydrochloride ingredient
Treatment:
Upneeq is used for correcting drooping eyelids.
Dosage:
Upneeq is available in solution/drops form for ophthalmic use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.1% | SOLUTION/DROPS | Prescription | OPHTHALMIC |